Monoclonal Anti-Tumor Necrosis Factor Receptor II antibody produced in mouse
SIGMA/T1815 - clone 22221, purified immunoglobulin, lyophilized powder
Synonym: Anti-TNF RII; Anti-TNFRSF1B
MDL Number: MFCD01633483
Product Type: Chemical
This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.
| antibody form | purified immunoglobulin |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | 22221, monoclonal |
| conjugate | unconjugated |
| form | lyophilized powder |
| isotype | IgG2a |
| Quality Level | 200  |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunocytochemistry: 8-25 μg/mL using immersion fixed human peripheral blood lymphocytes |
| microarray: suitable | |
| neutralization: suitable | |
| UniProt accession no. | P01375  |
| Application: | Anti-Tumor Necrosis Factor Receptor II antibody may be used for immunocytochemistry at a working concentration of 8-25 μg/ml using human peripheral blood lymphocytes. The antibody is suitable for neutralization assays and protein microarray. The antibody was used for flow cytometry using human CD8 T cells. |
| Biochem/physiol Actions: | The antibody neutralizes the biological effect of recombinant human TNF RII. It does not neutralize or cross-react with TNF RI. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | The tumor necrosis factor super family (TNFSF) consists of at least 19 transmembrane proteins with soluble forms that are generated by proteolysis. The biological effects of TNF are mediated by either type I or type II receptors. Type I receptors that are ubiquitously present on all cells whereas type II receptors are expressed only on cells of immune system (monocytes, macrophages, Langerhans cells) and endothelial cells. Receptors of TNFSF such as TNFR I and Fas have their own death domains that activate the apoptosis. Other receptors such as TNFR II do not have death domains and utilize TNF associated factors (TRAFs) to activate intracellular signaling. TNFR II activates NF-κB pathway via the activation of NIK. Monoclonal Anti-Tumor Necrosis Factor Receptor II antibody recognizes human TNFR II. |
| Immunogen: | recombinant human tumor necrosis factor receptor II, expressed in Escherichia coli. |
| Physical form: | Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates. |
| Preparation Note: | Purified using protein A |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |